BioAge Labs, Inc. - Common Stock (BIOA)

EMERYVILLE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced a proposed underwritten public offering in which it intends to offer and sell, subject to market and other conditions, up to $75.0 million of shares of its common stock. In addition, BioAge intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of its common stock. All of the shares of common stock are being offered by BioAge. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated with intravitreal therapies

First BGE-102 MAD cohort completed in obese individuals with elevated hsCRP receiving 120 mg QD; demonstrated rapid and profound reduction in inflammatory markers

Don't be too quick to jump on this biotech bandwagon.

BGE-102 was well-tolerated in SAD and initial MAD cohorts, with a pharmacokinetic profile supporting once-daily oral dosing

EMERYVILLE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Piper Sandler 37th Annual Healthcare Conference taking place in New York, NY on December 2-4, 2025.

EMERYVILLE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Jefferies Global Healthcare Conference in London, November 17–20, 2025.

BioAge Labs reported a mixed Q3 2025, beating revenue estimates by 94% with a narrower EPS loss. The clinical-stage biotech advanced its lead drug, BGE-102, with cash runway through 2029.

First participant dosed in Phase 1 trial of BGE-102, oral CNS-penetrant NLRP3 inhibitor, with initial SAD data expected by year-end

The bank's lead analyst recognizes the importance of getting in early with potentially game-changing drug development.

This stock has caught fire after some recent events, but how long will that last?

The clinical-stage biotech is working on a new type of weight management drug.

Intrigued by the market activity one hour before the close of the markets on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session.

Discover the top movers in Thursday's pre-market session and stay informed about market dynamics.

NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) --

EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:

First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile

Oral NLRP3 inhibitor BGE-102 on track for Phase 1 initiation in 2H 2025 with initial data by year-end